FOLLOW-UP CARE AFTER
CANCER TREATMENT ABROAD
A complete guide to managing your health after cancer treatment in China or another international centre โ from the moment you return home through ongoing surveillance, medication management, and when to return for further treatment cycles.
analyticsAt a Glance
- check_circleThe transition from treatment centre to home is one of the highest-risk periods for care gaps โ planning it carefully is essential
- check_circleA well-translated discharge summary is the single most important document for your home oncologist
- check_circleSome medications dispensed in China are not available in all home markets โ advance planning prevents treatment interruption
- check_circleCancerFax remains your active coordination bridge between the overseas centre and your home healthcare team after you return
Why Follow-Up Planning Is as Important as the Treatment Itself
The clinical benefit of cancer treatment abroad can be fully realised only if follow-up care is managed effectively at home. Gaps in surveillance, missed medication doses, or a home oncologist who does not understand the treatment that was given can all erode the gains achieved during treatment. Planning the transition before you leave the overseas centre โ not after you arrive home โ is the right approach.
โThe treatment abroad is the beginning of the plan, not the end of it. What happens in the months after you return home determines how much benefit you actually retain.โ
The Transition Risk Period
The period immediately after returning home โ particularly the first 4โ8 weeks โ carries the highest risk of care gaps. This is when side effects from treatment may still be active, when surveillance imaging is first due, and when the home oncologist is still learning what treatment was given. Proactive planning during this window is essential.
Two Clinical Teams, One Patient
After treatment abroad, you have at minimum two oncology teams involved in your care โ the overseas treating centre and your home oncologist. Without active coordination, these teams may be unaware of each other's assessments, prescriptions, and plans โ creating the conditions for contradictory advice and medication errors.
The Complete Transition Checklist โ Before You Leave the Treatment Centre
These are the steps that must be completed before you leave the overseas hospital โ or in the first days after returning home. CancerFax manages most of these on your behalf.
- 1
Obtain a Complete Discharge Summary
Request a comprehensive discharge summary from the treating oncologist before leaving the hospital. This should include your diagnosis, staging, treatment received (drug names, doses, cycle numbers, dates), response assessment, active side effects, and the recommended follow-up plan. The summary is the clinical handover document that your home oncologist will rely on.
- 2
Get Everything Translated Into English
If the discharge summary, investigation reports, and prescription information are in Mandarin or another language, arrange professional medical translation before returning home. CancerFax translates all discharge documentation โ including drug names in Chinese to generic international names โ and delivers translated documents within 48 hours of receipt.
- 3
Clarify Your Follow-Up Imaging Schedule
Confirm with the treating oncologist: which imaging modality is recommended (CT, MRI, PET-CT), which body areas to scan, how frequently, and what specific findings would trigger a return visit or treatment escalation. Document this in writing โ 'CT chest/abdomen/pelvis every 3 months for 2 years' is actionable; 'follow up as needed' is not.
- 4
Clarify Medication Continuation at Home
If you are leaving with ongoing oral medications โ targeted therapy, oral chemotherapy, anti-epileptics, steroids โ confirm whether these are available in your home country. For Chinese domestic agents (sintilimab, apatinib, abiraterone equivalent), availability outside China may be limited. CancerFax advises on which medications require advance planning and assists with obtaining sufficient supply to bridge until your home system can arrange continuation.
- 5
Arrange a Handover Consultation With Your Home Oncologist
Before or immediately after returning home, schedule a dedicated consultation with your home oncologist โ not to restart from scratch, but to present the translated discharge summary and align the ongoing surveillance and treatment plan. CancerFax can prepare a concise briefing document for your home oncologist summarising what was done and what is recommended next.
- 6
Schedule Your First Post-Return Follow-Up Imaging
Arrange the first post-return imaging appointment before you leave the treating centre if possible โ so the date is confirmed and recorded in your home system. Day 30 and day 90 response assessment imaging after CAR-T, cell therapy, or novel agent infusion are time-sensitive and should be booked proactively.
Follow-Up Plan by Treatment Type
A reference guide to the typical surveillance schedule and key follow-up considerations for the most common treatment types accessed by CancerFax patients at overseas centres.
| Treatment Type | Surveillance Imaging | Key Monitoring | Return Visit Triggers |
|---|---|---|---|
| Chemotherapy (FOLFOX/XELOX/SOX) | CT every 2โ3 cycles (6โ9 weeks) during treatment; every 3 months post-treatment | FBC, LFTs, neuropathy (oxaliplatin), hand-foot reaction (capecitabine) | Disease progression on CT; new symptoms; grade 3+ toxicity |
| PD-1 checkpoint inhibitor | CT every 8โ12 weeks; baseline lung imaging before each cycle | Thyroid function, LFTs, FBC; watch for irAEs (colitis, pneumonitis) | Any new respiratory symptoms (ILD); diarrhoea grade 2+; rash; new organ dysfunction |
| T-DXd (trastuzumab deruxtecan) | CT every 6โ8 weeks during treatment | Respiratory symptoms and chest CT for ILD monitoring at every visit | Any new cough, dyspnoea, or chest imaging change โ ILD is the key safety signal |
| CAR-T cell therapy | PET-CT or CT at day 30 and day 90 post-infusion; bone marrow biopsy (haematological) | FBC, CRP, ferritin (late CRS/HLH); MRD testing (haematological) | Febrile neutropenia; neurological symptoms; failure to achieve remission at day 30 |
| CIK therapy | CT/MRI and tumour markers every 2โ3 CIK cycles | AFP (HCC), CEA/CA19-9 (gastric/CRC); FBC for immune recovery | Tumour marker rise; new lesion on imaging; persistent fever post-infusion |
| Zolbetuximab | CT every 6โ8 weeks during treatment | Nausea/vomiting management; weight; nutritional status | Disease progression; new hepatic lesions; grade 3+ GI toxicity |
| Proton/Heavy Ion therapy | MRI 6โ8 weeks post-treatment; then every 3 months | Local control assessment; irradiation-field tissue reactions | Local recurrence on imaging; new neurological symptoms (CNS tumours) |
Managing Medication Continuity After China Treatment
One of the most practically challenging aspects of returning home after treatment in China is ensuring continuity of medications โ particularly for agents that are China-approved but not available in the home market.
Medications Typically Available Internationally
- Nivolumab / pembrolizumab (originator)FDA/EMA-approved โ available in most countries with oncology prescribing infrastructure, though cost may be prohibitive without insurance or national healthcare coverage.
- T-DXd (Enhertu)FDA/EMA/NMPA approved โ available in most major markets; may require home oncologist prescribing and insurance pre-authorisation.
- Trastuzumab (originator or approved biosimilar)Widely available internationally โ may require switching from a Chinese biosimilar to an approved version in your home market.
- Oral capecitabine, oxaliplatinStandard chemotherapy agents available at virtually all oncology pharmacies internationally.
Medications Requiring Advance Planning
- Chinese domestic PD-1 inhibitors (sintilimab, camrelizumab)NMPA-approved only โ not available outside China, South Korea, and a small number of other markets. If continued treatment is planned, patients must return to China for infusions or switch to an internationally approved equivalent with oncologist guidance.
- Chinese domestic TKIs (apatinib, anlotinib, RC48)Chinese domestic agents with NMPA approval only โ not available on international formularies. Patients on these agents must plan continuation supply before leaving China.
- CIK cell therapy infusionsCIK therapy requires GMP-certified laboratory manufacturing โ not available outside China and East Asia. Subsequent CIK cycles require return visits to China or equivalent centres in the region.
- Oral S-1 (tegafur/gimeracil/oteracil)S-1 is widely used in Japanese and Chinese gastric cancer protocols but is not approved in the USA or many European markets. Equivalent capecitabine may be substituted with oncologist guidance.
Follow-Up After Cancer Treatment Abroad โ Key Numbers
Practical reference figures that underscore the importance of structured post-treatment follow-up planning.
- 48 hrsCancerFax discharge document translation turnaroundTranslated discharge summary, prescriptions, and follow-up instructions delivered to you and your home oncologist within 48 hours of receiving the original documents.
- Day 30 / Day 90Standard post-infusion response assessment milestones for CAR-T and novel cell therapyThese time-sensitive imaging assessments must be booked proactively โ missing them delays clinical decision-making at a critical early window.
- ~30%Proportion of patients whose home oncologist requests additional information from the overseas treating centreBased on CancerFax coordination experience โ a direct oncologist-to-oncologist briefing letter significantly reduces this figure and accelerates home care continuity.
Complete Your International Cancer Treatment Journey
Explore the full CancerFax preparation and access library โ from record preparation and visa logistics to treatment costs and how we help.
Frequently Asked Questions About Follow-Up After Cancer Treatment Abroad
My home oncologist has never heard of the treatment I received in China. What do I do?
This is common โ particularly for treatments like CIK therapy, zolbetuximab, or Chinese domestic PD-1 inhibitors that are not yet standard-of-care in Western countries. CancerFax prepares a dedicated briefing document for your home oncologist โ a concise, referenced clinical summary of the treatment received, the evidence supporting it, the response assessment results, and the recommended follow-up plan โ designed specifically for an oncologist unfamiliar with the therapy. We are also available to facilitate a direct conversation between your home oncologist and the Chinese treating team if more detailed clinical discussion is needed.
Can I continue sintilimab (or another Chinese PD-1 inhibitor) at home after returning from China?
Sintilimab, camrelizumab, and other Chinese domestic PD-1 inhibitors are NMPA-approved in China but are not approved in the USA, EU, or most other Western markets. This means your home oncologist cannot prescribe them, and your local pharmacy cannot dispense them. If continued PD-1 inhibitor therapy is part of your treatment plan, there are two options: return to China for continuation infusions, or transition to a locally approved PD-1 inhibitor equivalent (pembrolizumab or nivolumab) with your home oncologist's guidance. CancerFax advises on the clinical and practical considerations of both pathways before you leave China.
How does CancerFax support me after I return home?
Our coordination does not end at hospital discharge. After you return home, CancerFax provides: translation and delivery of your discharge documents to your home oncologist, a clinical briefing letter summarising treatment and follow-up recommendations, scheduling support for return-visit CIK cycles or CAR-T monitoring visits, a communication channel between you and the Chinese treating team for any clinical questions that arise, and active guidance on medication continuity where Chinese domestic agents were prescribed. Most patients stay in contact with CancerFax throughout their full treatment programme โ typically 6โ18 months post-first-visit.
What are the signs that I should contact the overseas treatment centre urgently after returning home?
Contact the overseas treating centre (via CancerFax) urgently if you experience: new or worsening respiratory symptoms after T-DXd or checkpoint inhibitor therapy (possible ILD or pneumonitis); fever above 38.5ยฐC in the first 4 weeks after CAR-T infusion (late CRS or infection); new neurological symptoms after CAR-T (late ICANS); severe diarrhoea, colitis symptoms, or jaundice after checkpoint inhibitor therapy (irAEs); or any new symptom that the Chinese treating team specifically warned you about in your discharge instructions. For any emergency, always contact your local emergency services first โ use the overseas centre for clinical guidance after immediate safety is secured.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
CancerFax Stays With You After You Return Home
Our coordination does not end when you leave the hospital. CancerFax translates discharge documents, liaises with your home oncologist, manages return visit scheduling, and provides an active point of contact between you and the Chinese treatment centre for as long as you need it.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making any changes to your treatment plan.